# Liposomal Bupivacaine Single-Injection Interscalene Block vs. Continuous Interscalene Block for Primary Total Shoulder Arthroplasty

> **NCT05005260** · PHASE4 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 88 (actual)

## Conditions studied

- Pain, Postoperative
- Brachial Plexus Block

## Interventions

- **DRUG:** Bupivacaine HCl
- **DRUG:** Liposomal bupivacaine + Bupivacaine Hcl 0.5% Inj

## Key facts

- **NCT ID:** NCT05005260
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-14
- **Primary completion:** 2023-03-18
- **Final completion:** 2023-03-18
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2024-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05005260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05005260, "Liposomal Bupivacaine Single-Injection Interscalene Block vs. Continuous Interscalene Block for Primary Total Shoulder Arthroplasty". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05005260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*